Vancomycin-resistant enterococcus bloodstream infection successfully managed with oritavancin and fosfomycin as sequential treatment
- 21 August 2023
- journal article
- research article
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 36 (1) , 31-34
Abstract
Bloodstream infections caused by vancomycin-resistant enterococci are increasingly reported and a consensus therapy does not exist. Oritavancin has shown good antimicrobial activity against VRE, but its use is mainly limited to skin, soft tissue, and/or bone infections. Fosfomycin is increasingly used for enterococcal infections (including bloodstream infections and endocarditis) as a partner drug given its anti-biofilm and synergistic properties. Recently in vitro and in vivo synergism between oritavancin and fosfomycin against VRE isolates has been demonstrated. Herein we report the case of a hematologic patient with a VRE bloodstream infection successfully treated with oritavancin and fosfomycin as sequential treatment.Keywords
This publication has 7 references indexed in Scilit:
- In Vitro and In Vivo Studies of Oritavancin and Fosfomycin Synergism against Vancomycin-Resistant Enterococcus faeciumAntibiotics, 2022
- Short-course versus long-course antibiotic treatment for uncomplicated vancomycin-resistant enterococcal bacteraemia: a retrospective multicentre cohort studyClinical Microbiology and Infection, 2022
- Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010–2019)Antimicrobial Agents and Chemotherapy, 2022
- Trends in the Incidence and Antibiotic Resistance of Enterococcal Bloodstream Isolates: A 7-Year Retrospective Multicenter Epidemiological Study in ItalyMicrobial Drug Resistance, 2021
- Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled TrialClinical Infectious Diseases, 2018
- Combatting resistant enterococcal infections: a pharmacotherapy reviewExpert Opinion on Pharmacotherapy, 2018
- Thrombocytopenia with Tedizolid and LinezolidAntimicrobial Agents and Chemotherapy, 2018